On May 16, 2018 Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin therapies*, reported that the complete safety and efficacy results of the Phase 1 study of its lead proprietary oncology drug, MP0250, will be presented at the Annual Meeting 2018 of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) in Chicago (Press release, Molecular Partners, MAY 16, 2018, View Source [SID1234526673]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
MP0250 is a multi-DARPin candidate targeting simultaneously VEGF and HGF, two prominent escape pathways, and has the potential to reverse resistance that has built to standard of care cancer therapies. MP0250 is currently evaluated in a Phase 2 study in combination with bortezomib and dexamethasone in patients with relapsed refractory multiple myeloma. An additional Phase 1b/2 study will evaluate MP0250 in combination with osimertinib in patients with EGFR-mutated NSCLC (Non-small cell lung cancer).
The data to be presented at ASCO (Free ASCO Whitepaper) include the complete safety and efficacy results and pharmacokinetics data from the First-in Human Phase 1 study of MP0250 in advanced solid tumor patients.
"We are very pleased with the Phase 1 data of MP0250," commented Andreas Harstrick, Chief Medical Officer of Molecular Partners. "MP0250 was well tolerated and about half of the patients stayed on treatment for three months or longer, with the longest treatment duration beyond one year. We are looking forward to additional results from our Phase 2 combination studies."
The MP0250 data will be presented in the following sessions:
Monday, June 4, 2018, 8.00 am ET, Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics / Abstract 2520 (Poster Board: #346):
First-in-class phase I study evaluating MP0250, a VEGF and HGF neutralizing DARPin molecule, in patients with advanced solid tumors (Azaro et al.)
Monday, June 4, 2018, 3:00 pm – 4:15 pm ET, room S406:
Discussion of the abstract at the Poster Discussion Session
Full details on the Molecular Partners’ session at ASCO (Free ASCO Whitepaper) 2018 as well as all presentations can be found here. Following its presentation at the ASCO (Free ASCO Whitepaper), the poster will also be available one the Molecular Partners website.
*DARPin is a registered trademark owned by Molecular Partners AG.
Financial Calendar
August 30, 2018 – Publication of 2018 Half-year Results
November 01, 2018 – Q3 2018 Management Statement
View Source
About the DARPin Difference
DARPin therapeutics are a new class of protein therapeutics opening an extra dimension of multi-specificity and multi-functionality. DARPin candidates are potent, specific, safe and very versatile. They can engage in more than 5 targets at once, offering potential benefits over those offered by conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology is a fast and cost-effective drug discovery engine, producing drug candidates with ideal properties for development and very high production yields.
With their good safety profile, low immunogenicity and long half-life in the bloodstream and the eye, DARPin therapies have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. Molecular Partners is partnering with Allergan to advance clinical programs in ophthalmology, and is advancing a proprietary pipeline of DARPin drug candidates in oncology. The most advanced global product candidate is abicipar, a molecule currently in Phase 3, in partnership with Allergan.
Several DARPin molecules for various ophthalmic indications are also in development. The most advanced systemic DARPin molecule, MP0250, is in Phase 1 clinical development for the treatment of solid tumors and in Phase 2 development for hematological tumors. In addition, Molecular Partners intends to further evaluate MP0250 for solid tumors in a phase 1b/2 trial for EGFR-mutated NSCLC. MP0274, the second-most advanced DARPin drug candidate in oncology, has broad anti-HER activity; it inhibits HER1, HER2 and HER3-mediated downstream signaling via Her2, leading to induction of apoptosis. MP0274 has moved into Phase 1. Molecular Partners is also advancing a growing preclinical pipeline that features several immuno-oncological development programs. DARPin is a registered trademark owned by Molecular Partners AG.